Correlation Analyses of Imetelstat Exposure with Pharmacodynamic Effect, Efficacy and Safety in a Phase 2 Study in Patients with Higher-Risk Myelofibrosis Refractory to Janus Kinase Inhibitor Identified an Optimal Dosing Regimen for Phase 3 Study
Year: 2020
Type: article
Source: Blood
Authors: John Mascarenhas, Rami S. Komrokji, Michele Cavo, Bruno Martino, Dietger Niederwieser, Andreas Reiter, Bart L. Scott, Maria R. Baer, Ronald Hoffman, Olatoyosi Odenike, Laurie Sherman, Souria Dougherty, Tymara Berry, Faye Feller, Libo Sun, Ying Wan, Aleksandra Rizo, Fei Huang, Jean-Jacques Kiladjian
Institutions: Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Moffitt Cancer Center, University of Bologna, Azienda ospedaliera "Bianchi-Melacrino-Morelli", University Hospital Leipzig, University Medical Centre Mannheim, Fred Hutch Cancer Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Chicago, Geron (United States), Hôpital Saint-Louis
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3095596782